Abstract
BackgroundNon-engineered tumor-infiltrating lymphocyte (TIL) cell therapy has demonstrated antitumor activity in metastatic NSCLC.1 2 Historically, surgical tumor tissue procurement has been required to manufacture TIL, but surgery is a barrier...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
